Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.
Quanterix Corporation (NASDAQ: QTRX) generates news that spans scientific breakthroughs, clinical research, corporate developments, and financial performance, all centered on its ultra-sensitive Simoa biomarker detection technology and spatial biology capabilities. As a life sciences company active in testing laboratories and professional scientific services, Quanterix regularly reports on studies, collaborations, and product launches that affect disease research and diagnostics.
Investors and researchers following QTRX news will see coverage of peer‑reviewed studies that rely on Simoa assays, such as large population-based analyses of Alzheimer’s Disease Neuropathological Changes using p‑Tau 217, and multiple sclerosis research that combines GFAP and NfL biomarkers for personalized monitoring. These articles illustrate how Quanterix assays and reference databases are applied in real-world clinical and epidemiological settings.
The company also issues updates on new assay launches and platform enhancements, including commercial introductions of p‑Tau 205 and p‑Tau 212 assays for Alzheimer’s research, and developments at the Quanterix Accelerator Laboratory, which supports clinical testing and global clinical trials. News items may highlight regulatory milestones, such as clinical laboratory permits and medical device registrations for specific assay kits in various markets.
From a corporate and capital markets perspective, Quanterix news includes quarterly financial results, non‑GAAP performance metrics, and commentary on integration progress following its acquisition of Akoya Biosciences. Filings and press releases discuss cost synergies, revenue composition across product and service lines, and governance changes such as cooperation agreements with shareholders and Board structure updates.
This QTRX news page brings together these updates so readers can track scientific publications, diagnostic advancements, spatial biology integration, and financial disclosures in one place.
Quanterix Corporation (NASDAQ: QTRX) announced that its CEO, Masoud Toloue, will present at Cowen’s 43rd Annual Health Care Conference on March 7, 2023, at 9:50 a.m. EST. The conference occurs from March 6-8, 2023, at the Boston Marriott Copley Place. Quanterix will host one-on-one meetings with institutional investors during the event. The presentation will be available via live audio webcast, and replays will be accessible afterward on the company's investor relations page. Quanterix specializes in ultrasensitive biomarker detection through its Simoa® technology, contributing to advancements in various fields including neurology and oncology.
Quanterix Corporation (NASDAQ: QTRX) announced a conference call scheduled for March 6, 2023, at 8:30 AM Eastern Time to discuss its fourth quarter and full year 2022 financial results. The call will be led by Masoud Toloue, President and CEO, and Michael Doyle, CFO. A press release with detailed earnings information will precede the call, available on the Quanterix website. Quanterix specializes in ultrasensitive biomarker detection, leveraging its Simoa® technology for breakthroughs in various disease areas. The company has been a longstanding partner in scientific research, contributing to over 2,000 peer-reviewed journals.
NATICK, Mass. - Mercy BioAnalytics announced that Dawn Mattoon, PhD, has taken over as Chief Executive Officer, transitioning from her previous role as Chief Operating Officer. Paul Blavin has moved to the position of Vice Chairman of the Board. Dr. Mattoon, who has been with the company for seven months, praised the team's progress in advancing their cancer detection technology. Her experience includes leadership roles in strategic initiatives at companies like Quanterix and Thermo Fisher Scientific. The company focuses on the early detection of cancers, particularly ovarian and lung cancers, through its Mercy Halo liquid biopsy platform.
Quanterix Corporation (NASDAQ: QTRX) appointed Brian Blaser to its Board of Directors on January 6, 2023. With over 25 years in the in-vitro diagnostics field, including 15 years at Abbott Laboratories, Blaser's leadership experience enhances the board's expertise. He has a proven track record in launching diagnostic products and implementing growth strategies. CEO Masoud Toloue emphasized Blaser's operational excellence, which aligns with Quanterix’s future diagnostics initiatives. Blaser holds an MBA from the Rochester Institute of Technology and a Bachelor's in Mechanical Engineering Technology from the University of Dayton.
Quanterix Corporation (NASDAQ: QTRX) has announced the validation of a new CLIA blood test to quantitatively measure neurofilament light chain (NfL) levels in serum. This test aids in assessing neurodegenerative conditions and neuronal damage. NfL is a crucial biomarker for various neurological disorders, and the Simoa NfL test is widely recognized for its clinical relevance. The FDA previously granted Breakthrough Device designation for this test in relation to multiple sclerosis. This launch aims to enhance clinical diagnostics and support future therapeutic trials.
Quanterix Corporation (NASDAQ: QTRX) announced that CEO Masoud Toloue will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 12, 2023, at 12 p.m. PST. The presentation will be accessible to attendees and the public via a live audio webcast. Quanterix will also hold one-on-one meetings with institutional investors during the event. Replays of the webcast will be available for a limited time afterward. Quanterix specializes in ultrasensitive biomarker detection, enabling significant advancements in various disease research.
Quanterix Corporation (NASDAQ: QTRX) announced the role of its ultrasensitive Simoa technology in advancing clinical trials for Alzheimer’s disease (AD), presented at the 15th Clinical Trials on Alzheimer's Disease conference in San Francisco. Eisai and Biogen showcased Phase 3 trial results for lecanemab, highlighting biomarker engagement. Additional data from Eli Lilly and Janssen emphasized plasma biomarker utility. Quanterix aims to support future AD therapeutic trials with innovative testing tools, including FDA-designated Breakthrough Devices expected in 2023.
Quanterix Corporation (NASDAQ: QTRX) will participate in the 15th Clinical Trials on Alzheimer's Disease (CTAD) from November 29 to December 2, 2022, in San Francisco. CEO Masoud Toloue is set to present on the advantages of blood-based biomarkers such as pTau-181 and pTau-217 over traditional PET scans for clinical trial efficiency and patient monitoring. These biomarkers have shown promise in Phase III trials, facilitating the design of effective Alzheimer’s disease treatments. The conference aims to accelerate collaboration among leaders in Alzheimer’s research.
Quanterix Corporation (NASDAQ: QTRX) announced that President and CEO Masoud Toloue and CFO Michael Doyle will present at the CG MedTech, Diagnostics and Digital Health & Services Forum on November 17, 2022, at 4:30 p.m. EST in Boston, MA. They will engage in one-on-one and group meetings with institutional investors on the same day. A live webcast of the presentation will be available on Quanterix's Investor website, with replays accessible for 90 days. Quanterix specializes in ultrasensitive biomarker detection aimed at advancing research in various medical fields.
Quanterix Corporation (NASDAQ: QTRX) reported flat revenue of $26.6M for Q3 2022 compared to Q3 2021, up 13% from Q2 2022. Pro-forma gross margin was 35%, down 1470 bps year-over-year but up 670 bps quarter-over-quarter. The company is progressing in the Bio-Hermes trial and received funding from the Alzheimer’s Drug Discovery Foundation to advance Alzheimer's diagnostic tests. However, the restructuring has incurred significant charges, including $8.2M in goodwill impairment. Q3 net loss reached $35.1M, a substantial increase from $15.7M in Q3 2021.